Growth Metrics

Supernus Pharmaceuticals (SUPN) Liabilities and Shareholders Equity (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Liabilities and Shareholders Equity for 15 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 6.18% to $1.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $5.6 billion, a 5.09% increase, with the full-year FY2025 number at $1.5 billion, up 6.18% from a year prior.
  • Liabilities and Shareholders Equity was $1.5 billion for Q4 2025 at Supernus Pharmaceuticals, up from $1.4 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.8 billion in Q1 2023 to a low of $1.3 billion in Q4 2023.
  • A 5-year average of $1.5 billion and a median of $1.4 billion in 2025 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: grew 26.69% in 2021, then fell 27.22% in 2024.
  • Supernus Pharmaceuticals' Liabilities and Shareholders Equity stood at $1.7 billion in 2021, then rose by 0.79% to $1.7 billion in 2022, then dropped by 24.95% to $1.3 billion in 2023, then rose by 7.08% to $1.4 billion in 2024, then grew by 6.18% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Liabilities and Shareholders Equity are $1.5 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.4 billion (Q2 2025).